Peer Review reports
From: Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study
| Original Submission | ||
|---|---|---|
| 21 Aug 2023 | Submitted | Original manuscript |
| 13 Oct 2023 | Reviewed | Reviewer Report |
| 4 Dec 2023 | Author responded | Author comments - Feng Wang |
| 4 Apr 2024 | Reviewed | Reviewer Report |
| 8 Apr 2024 | Reviewed | Reviewer Report |
| 11 May 2024 | Author responded | Author comments - Feng Wang |
| Resubmission - Version 2 | ||
| 4 Dec 2023 | Submitted | Manuscript version 2 |
| 14 May 2024 | Author responded | Author comments - Feng Wang |
| Resubmission - Version 3 | ||
| 14 May 2024 | Submitted | Manuscript version 3 |
| 14 Jun 2024 | Author responded | Author comments - Feng Wang |
| Resubmission - Version 4 | ||
| 14 Jun 2024 | Submitted | Manuscript version 4 |
| Publishing | ||
| 17 Jun 2024 | Editorially accepted | |
| 4 Jul 2024 | Article published | 10.1186/s13019-024-02940-3 |
You can find further information about peer review here.